Rheumatoid Arthritis and Myositis Cohort
The primary objective of this research is to establish a well characterized clinical and longitudinal cohort for individuals with Rheumatoid Arthritis (RA) and Myositis to create a place to maintain blood, urine, stool specimens, excess tissue from procedures, and clinical data, which may be accessed for future research purposes.
Specific research objectives of this cohort include:
Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis.
Observe the role that the intestinal microbiome has on the immune cell population and cytokines in individuals with RA or Myositis.
Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.
Telehealth-delivered HealthcaRe to ImproVe Care (THRIVE) as an Integral Component of Remote Therapeutic Monitoring (RTM)
Objective 1:
Evaluate patients' satisfaction with their telehealth care and determine factors associated with satisfaction.
Objective 2:
Deploy PROs and patient self-assessment tools, specifically a patient-facing instructional in-app tool that instructs RA patients how to perform self-assessment examinations to observe and report the number of tender and swollen joint counts.
Anti-Inflammatory Dietary Intervention for Rheumatoid Arthritis
The primary objective of this study is to assess if there is a significant difference in the mean disease activity score in individuals with RA participating in a dietary intervention compared to those in the control group measured by DAS-28. Other measures to track disease activity will include monitoring number and severity of disease flares and any changes in medications. This will be done by completing a single-blinded randomized controlled trial, parallel in design. The study population will consist of adults diagnosed with Seropositive and Seronegative RA based on the American College of Rheumatology criteria. Participants will have low, moderate, or high disease activity based on DAS-28 where the investigator feels that they can see improvement from a dietary intervention.
100 项与 Attune Health Research, Inc. 相关的临床结果
0 项与 Attune Health Research, Inc. 相关的专利(医药)
100 项与 Attune Health Research, Inc. 相关的药物交易
100 项与 Attune Health Research, Inc. 相关的转化医学